NextPoint is a company focused on precision immuno-oncology and tumor-targeting therapeutics. They work on the B7-H7/HHLA2 axis, integrating foundational science with a defined clinical biomarker to identify patient populations for B7-H7-directed therapy.

NextPoint

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 checkpoint axis. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simultaneously advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology and beyond.

Sixty Degree Capital

Sanofi Ventures

PagodaTree Partners

Leaps by Bayer

MPM Capital

Invus

Binney Street Capital

Catalio Capital Management

Gordon Freeman

NextPoint Therapeutics, Inc.

#ICYMI, be sure to check out the poster @NextPoint presented at CIMT in May: “Targeting B7-H7-mediated immunosuppression with NPX267 and NPX887, two fully humanized monoclonal antibodies that target KIR3DL3 and B7-H7, respectively”

For more information on how NextPoint’s new class of therapeutics may improve treatment options for cancer patients who do not respond to PD-1/L1 therapy, visit: nextpointtx.com.

We are thrilled to announce that our CEO, Ivan Cheung, will be speaking at the Longwood Healthcare Leaders Spring MIT event! Join us for two days of discussion and networking with biopharmaceutical leaders. Co-hosted by Koch Institute Professors Phil Sharp and Bob Langer and held at MIT’s Koch Institute, June 17-18, 2024. 

https://lnkd.in/exxKDits

Longwood Healthcare Leaders Longwood Fund #longwoodhealthcareleaders

Chief Medical Officer Leena Gandhi spoke last week at the Next-Gen Immuno-Oncology Conference in Boston about NextPoint Therapeutics, Inc.'s novel class of therapeutics targeting the B7-H7 pathway to improve treatment options for cancer therapy.

For more information on NextPoint’s new class of therapeutics to improve treatment options for cancer patients who do not respond to PD-1/L1 therapy, visit: nextpointtx.com.

Congratulations to NextPoint co-founder Dr. Gordon Freeman!

A nice behind the scenes look at how NextPoint scientific co-founder XingXing Zang's research translated to NPX267, our first clinical immuno-oncology program, currently in Phase 1a/1b clinical trials.

As we continue to push the boundaries of possibility, we are immensely grateful to be part of the LabCentral community.  LabCentral is the heart of our innovation and we're excited to share the impressive success of LabCentral and their 2023 Impact Report.

https://lnkd.in/eAxUk4T3

LabCentral has state-of-the-art facilities with access to top-tier resources where brilliant minds come together and make magic every day.  #Innovation #Collaboration #LabCentral #Science #Technology #Research

COM:NEXTPOINTTX

NextPoint

Analysis Not Available